EN
2026-07-01
Accréditation CAP

Recognition of the highest international quality standards

 

Cerba Advanced Pathology by Cerba has obtained accreditation from the College of American Pathologists (CAP) for several strategic areas, including immunology, molecular microbiology, and next‑generation sequencing applied to infectious diseases (Infectious Disease NGS).

As a global reference for laboratory excellence, the CAP accreditation program is based on inspections conducted by domain experts and on regularly updated standards designed to incorporate the latest scientific and technological advancements.
 

Access the CAP accreditation

A mark of trust for international clinical trials

Recognized by global players  in the pharmaceutical, biotechnology, and in vitro diagnostics industries, CAP accreditation strengthens Cerba’s ability to support clinical development programs on an international scale. We provide partners with the assurance that analyses are performed in an environment that meets the quality requirements expected for multicentric studies and the most complex projects.

Through its scientific expertise, central laboratory infrastructure, and internationally recognized quality standards, Cerba is a trusted partner for generating high‑quality biological data that supports the development of new diagnostic and therapeutic approaches.

Access the CAP accreditation

A Commitment to Quality for Our International Clients

CAP accreditation strengthens Cerba Advanced Pathology’s position as a leading provider of specialized medical laboratory services worldwide. Operating in more than 50 countries, we support laboratories and clinicians every day with testing services that meet the most stringent quality requirements. This internationally recognized accreditation highlights the excellence of our practices and the robustness of our processes, while further reinforcing our partners’ confidence in the quality, reliability, and accuracy of our results.

Access the CAP accreditation

This international recognition by the College of American Pathologists reflects our ongoing commitment to maintaining the highest quality standards. By mastering advanced technologies such as next‑generation sequencing, we accelerate the deployment of clinical trials.

Aurélie Driss Corbin

CEO of Cerba Laboratory